This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Last Updated: 11/18/2026
Milvexian is an oral investigational factor XIa inhibitor being studied for the prevention of major thrombotic conditions in a worldwide collaboration program between Bristol Myers Squibb and Johnson & Johnson. Milvexian is not currently approved for any use.
To read more about how Johnson & Johnson processes personal data, please visit https://innovativemedicine.jnj.com, select your country or region (in the upper right corner), and then click on Privacy Policy.
To read more about how Bristol Myers Squibb processes personal data, please visit https://www.bms.com, select your country (in the upper right corner), and then click on Privacy Policy.
LIBREXIA ACS1 was an international, randomized, double-blind, placebo-controlled,
event-driven phase 3 trial that evaluated the efficacy and safety of milvexian 25 mg added to SoC antiplatelet therapy among adult patients after a recent (within 7 days) ACS (N=14,194).
| Characteristic | Milvexian (n=7094) | Placebo (n=7100) |
|---|---|---|
| Age, years, mean (SD) | 63.1 (10.6) | 63.2 (10.5) |
| Age ≥65 years, n (%) | 3545 (50.0) | 3559 (50.1) |
| Male sex, n (%) | 5542 (78.1) | 5543 (78.1) |
| Medical history, n (%) | ||
| Hypertension | 5181 (73.0) | 5083 (71.6) |
| Diabetes | 3014 (42.5) | 3154 (44.4) |
| Prior coronary revascularization | 1808 (25.5) | 1726 (24.3) |
| Prior MI other than the index event | 1606 (22.6) | 1569 (22.1) |
| Type of index MI, n (%) | ||
| STEMI | 4085 (57.6) | 4067 (57.3) |
| NSTEMI | 2615 (36.9) | 2644 (37.2) |
| UA with elevated cardiac biomarkers | 393 (5.5) | 389 (5.5) |
| PCI performed for index MI, n (%) | 6516 (91.9) | 6496 (91.5) |
| Medications at the time of randomization, n (%) | ||
| Aspirin | 6884 (97.0) | 6893 (97.1) |
| P2Y12 inhibitor or other antiplatelet agent | 6885 (97.1) | 6880 (96.9) |
| Statin | 6607 (93.1) | 6628 (93.4) |
| Abbreviations: MI, myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; SD, standard deviation; STEMI, ST-segment elevation myocardial infarction; UA, unstable angina. | ||
The independent data monitoring committee recommended stopping the trial for futility based on the results of a prespecified interim analysis, with the recommendation accepted by the chair of the Program Executive Committee and a small group of unblinded sponsor representatives.
After a median follow-up of 12.2 months (interquartile range, 6.28-17.61), the primary endpoint event was reported in 384 (5.4%) patients in the milvexian group and 365 (5.1%) patients in the placebo group (HR, 1.05; 95% CI, 0.91-1.21; P=0.50). Results were consistent across all prespecified subgroups. The data for efficacy endpoints are listed in Table: Primary and Key Secondary Efficacy Outcomes.
| Outcome | Milvexian (n=7094) | Placebo (n=7100) | HR (95% CI) | ||
|---|---|---|---|---|---|
| n (%) | Event Rate per 100 Person-Years (95% CI) | n (%) | Event Rate per 100 Person-Years (95% CI) | ||
| Primary outcome | |||||
| CV death, MI, or ischemic strokea | 384 (5.4) | 5.60 (5.06-6.19) | 365 (5.1) | 5.33 (4.81-5.90) | 1.05 (0.91-1.21) |
| CV death | 110 (1.6) | 1.54 (1.28-1.86) | 112 (1.6) | 1.57 (1.30-1.89) | 0.98 (0.75-1.28) |
| MI | 249 (3.5) | 3.61 (3.19-4.09) | 236 (3.3) | 3.43 (3.02-3.89) | 1.05 (0.88-1.26) |
| Ischemic stroke | 60 (0.8) | 0.85 (0.66-1.10) | 46 (0.6) | 0.66 (0.49-0.88) | 1.30 (0.89-1.91) |
| Key secondary outcomes | |||||
| CV death, MI, ischemic stroke, major adverse limb events, or symptomatic VTE | 402 (5.7) | 5.87 (5.32-6.47) | 386 (5.4) | 5.65 (5.11-6.24) | 1.04 (0.90-1.20) |
| All-cause mortality, MI, and ischemic stroke | 430 (6.1) | 6.27 (5.70-6.89) | 408 (5.7) | 5.95 (5.40-6.56) | 1.05 (0.92-1.21) |
| CV death | 110 (1.6) | 1.54 (1.28-1.86) | 112 (1.6) | 1.57 (1.30-1.89) | 0.98 (0.75-1.28) |
| All-cause mortality | 158 (2.2) | 2.21 (1.89-2.59) | 164 (2.3) | 2.30 (1.97-2.68) | 0.96 (0.77-1.20) |
| Abbreviations: CI, confidence interval; CV, cardiovascular; HR, hazard ratio; MI, myocardial infarction; VTE, venous thromboembolism. aP=0.50. | |||||
The rates of safety outcomes appeared similar between the groups. Selected safety outcomes are listed in Table: Safety Outcomes.
| Outcome | Milvexian (n=7008) | Placebo (n=7027) | HR (95% CI) | ||
|---|---|---|---|---|---|
| n (%) | Event Rate per 100 Person-Years (95% CI) | n (%) | Event Rate per 100 Person-Years (95% CI) | ||
| Principal safety outcomeb | |||||
| BARC 3c and 5 bleedingc | 23 (0.3) | 0.37 (0.25-0.56) | 22 (0.3) | 0.36 (0.24-0.54) | 1.04 (0.58-1.87) |
| Key secondary safety outcomes | |||||
| BARC bleeding (type 3b, 3c, and 5) | 62 (0.9) | 1.01 (0.79-1.29) | 64 (0.9) | 1.04 (0.82-1.33) | 0.97 (0.68-1.37) |
| BARC 3b | 40 (0.6) | 0.65 (0.48-0.89) | 42 (0.6) | 0.68 (0.51-0.93) | 0.95 (0.62-1.47) |
| BARC 3c | 14 (0.2) | 0.23 (0.13-0.38) | 16 (0.2) | 0.26 (0.16-0.43) | 0.87 (0.43-1.79) |
| BARC 5 | 9 (0.1) | 0.15 (0.08-0.28) | 6 (0.1) | 0.10 (0.04-0.22) | 1.50 (0.53-4.21) |
| GUSTO severe or life-threatening bleeding event | 27 (0.4) | 0.44 (0.30-0.64) | 23 (0.3) | 0.37 (0.25-0.56) | 1.17 (0.67-2.04) |
| ISTH major bleeding | 105 (1.5) | 1.71 (1.41-2.07) | 102 (1.5) | 1.67 (1.37-2.02) | 1.03 (0.78-1.35) |
| Non-CABG-related TIMI major bleeding | 49 (0.7) | 0.80 (0.60-1.05) | 46 (0.7) | 0.75 (0.56-1.00) | 1.06 (0.71-1.59) |
| Adverse events | |||||
| Any AE | 3656 (52.2) | - | 3583 (51.0) | - | - |
| AEs leading to treatment discontinuation | 318 (4.5) | - | 333 (4.7) | - | - |
| SAEs | 819 (11.7) | - | 790 (11.2) | - | - |
| AE leading to death | 71 (1.0) | - | 73 (1.0) | - | - |
| Abbreviations: AE, adverse event; BARC, Bleeding Academic Research Consortium; CABG, coronary-artery bypass graft; CI, confidence interval; GUSTO, Global Use of Strategies to Open Occluded Coronary Arteries; HR, hazard ratio; ISTH, International Society of Thrombosis and Hemostasis; SAE, serious adverse event; TIMI, Thrombolysis in Myocardial Infarction. aIn the safety analysis, the principal and key secondary safety outcomes included data that were obtained from randomization through 2 days after administration of the last dose of milvexian or placebo. Data regarding AEs were obtained from the time of administration of the first dose of milvexian or placebo through 2 days after administration of the last dose, except for AEs leading to death, which could be recorded at any time after randomization. bThe BARC scale defines type 2 as clinically overt, actionable bleeding that prompts medical evaluation, minor nonsurgical treatment, or hospitalization; type 3b as overt bleeding with a decrease in hemoglobin of ≥5 g/dL, cardiac tamponade, bleeding requiring surgical control, or bleeding treated with intravenous vasoactive drugs; type 3c as intracranial or intraocular bleeding that compromises vision; and type 5 as fatal bleeding. cP=0.88. | |||||
A literature search of MEDLINE®
| 1 | Gibson CM, Steg PG, Bahit MC, et al. Milvexian with antiplatelet therapy after acute coronary syndrome event. [published online ahead of print August 29, 2026]. N Engl J Med. 2026. doi:10.1056/nejmoa2608717. |
Would you like to clear and leave your conversation? Message history will be lost.